Related Experiment Video
Updated: Jun 20, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Economic Evaluation of Empirical and Tailored Helicobacter pylori Eradication Strategies Including Second-Line
Joon Sung Kim1, Yuri Jeong2,3, Hankil Lee4
1Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Objectives:
To our knowledge, no study has evaluated the cost-effectiveness of tailored therapy guided by genotypic resistance compared with empirical clarithromycin-based triple therapy, including second-line therapies.
Methods:
A decision tree model was developed to compare empirical and tailored treatment strategies. Cost-minimization and cost-effectiveness analyses were conducted. The incremental cost-effectiveness ratio (ICER) was calculated to compare the two strategies, including second-line therapy.
Results:
The empirical therapy incurred a lower cost per patient (USD 211.49) than the tailored therapy (USD 269.88). The overall eradication rates were nearly identical (97.98% vs. 98.05%), yielding an ICER of USD 859.00 per 1% gain in eradication. Empirical therapy consistently resulted in lower total costs for all treatment durations. In the 7-day regimen, empirical therapy (USD 201.52; 97.64% eradication) versus tailored therapy (USD 253.62; 98.12%) produced an ICER of USD 108.54 per 1%, in favor of the empirical approach. In the 14‑day regimen, tailored therapy was more expensive (USD 282.74 vs. USD 221.46) and slightly less effective (97.97%, 98.34%). Overall, empirical therapy is a cost-effective strategy in most cases.
Conclusions:
This study demonstrates that tailored therapy guided by genotypic resistance is no more cost-effective than empirical therapy when second-line therapy is included. Future studies are warranted to identify strategies to improve the cost-effectiveness of tailored therapies in clinical practice.
More Related Videos
06:40Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
Published on: July 28, 2023
04:56Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...